A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Our product, the iLet Bionic Pancreas (iLet), was cleared by the U.S. Food and Drug Administration (FDA) for the treatment of Type 1 diabetes in adults and children six years and older and commercially launched in May 2023 in the United States. Since we began commercializing the iLet, our installed base has grown to 35,011 iLets as of December 31, 2025.
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 100M | 100M | 65M | - |
| Net Income | -73M | -73M | -55M | -44M |
| EPS | $-1.81 | $-1.81 | $-8.60 | $-8.31 |
| Free Cash Flow | -56M | -56M | -52M | -33M |
| ROIC | -21.5% | -74.6% | -30.2% | -32.6% |
| Gross Margin | 55.4% | 55.4% | 55.1% | - |
| Debt/Equity | 0.03 | 0.03 | -0.03 | -0.02 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -72M | -72M | -45M | -36M |
| Operating Margin | -71.5% | -71.5% | -69.5% | - |
| ROE | -25.5% | -346.5% | - | - |
| Shares Outstanding | 40M | 40M | 44M | 43M |
| Metric | 2023 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | 65M | 100M | 100M |
| Gross Margin | N/A | 55.1% | 55.4% | 55.4% |
| R&D | 18M | 26M | 35M | 35M |
| SG&A | 12M | 18M | 31M | 31M |
| EBIT | -36M | -45M | -72M | -72M |
| Op. Margin | N/A | -69.5% | -71.5% | -71.5% |
| Net Income | -44M | -55M | -73M | -73M |
| Net Margin | N/A | -84.1% | -73.0% | -73.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -32.6% | -30.2% | -74.6% | -21.5% |
| ROE | N/A | N/A | -346.5% | -25.5% |
| ROA | -40.1% | -36.6% | -30.6% | -22.3% |
| Cash Flow | ||||
| Op. Cash Flow | -32M | -48M | -51M | -51M |
| Free Cash Flow | -33M | -52M | -56M | -56M |
| Owner Earnings | -39M | -56M | -69M | -69M |
| CapEx | 402K | 3.4M | 5.3M | 5.3M |
| Maint. CapEx | 1.2M | 1.2M | 1.6M | 1.6M |
| Growth CapEx | 0 | 2.2M | 3.7M | 3.7M |
| D&A | 1.2M | 1.2M | 1.6M | 1.6M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 5.7M | 6.4M | 16M | 16M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -93M | -96M | -212M | -24M |
| Cash & Equiv. | 27M | 30M | 32M | 32M |
| Long-Term Debt | N/A | N/A | N/A | 7.4M |
| Debt/Equity | -0.02 | -0.03 | 0.03 | 0.03 |
| Interest Coverage | N/A | N/A | N/A | N/A |
| Equity | -203M | -245M | 288M | 288M |
| Total Assets | 110M | 150M | 329M | 329M |
| Total Liabilities | 51M | 74M | 41M | 41M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -230M | -297M | -370M | -370M |
| Working Capital | 93M | 112M | 237M | 237M |
| Current Assets | 104M | 133M | 268M | 268M |
| Current Liabilities | 11M | 21M | 31M | 31M |
| Per Share Data | ||||
| EPS | -8.31 | -8.60 | -1.81 | -1.81 |
| Owner EPS | -0.91 | -1.26 | -1.70 | -1.70 |
| Book Value | -4.69 | -5.53 | 7.11 | 7.11 |
| Cash Flow/Share | -0.75 | -1.09 | -1.26 | -1.77 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 43.3M | 44.4M | 40.4M | 40.4M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -6.5 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 4.5 | 1.7 |
| Price/Sales | N/A | N/A | 7.8 | 4.8 |
| FCF Yield | N/A | N/A | -4.4% | -11.8% |
| Market Cap | N/A | N/A | 1.3B | 478M |
| Avg. Price | N/A | N/A | 19.22 | 11.81 |
| Year-End Price | N/A | N/A | 31.86 | 11.81 |
Beta Bionics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 55.3%.
Beta Bionics, Inc. (BBNX) has a 5-year average return on invested capital (ROIC) of -45.8%. This is below average and may indicate limited pricing power.
Beta Bionics, Inc. (BBNX) has a market capitalization of $478M. It is classified as a small-cap stock.
Beta Bionics, Inc. (BBNX) does not currently pay a regular dividend.
Beta Bionics, Inc. (BBNX) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Beta Bionics, Inc. (BBNX) reported annual revenue of $100 million in its most recent fiscal year, based on SEC EDGAR filings.
Beta Bionics, Inc. (BBNX) has a net profit margin of -73.0%. The company is currently unprofitable.
Beta Bionics, Inc. (BBNX) generated $-56 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Beta Bionics, Inc. (BBNX) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
Beta Bionics, Inc. (BBNX) reported earnings per share (EPS) of $-1.81 in its most recent fiscal year.
Beta Bionics, Inc. (BBNX) has a return on equity (ROE) of -346.5%. A negative ROE may indicate losses or negative equity.
Beta Bionics, Inc. (BBNX) has a 5-year average gross margin of 55.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 3 years of financial data for Beta Bionics, Inc. (BBNX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Beta Bionics, Inc. (BBNX) has a book value per share of $7.11, based on its most recent annual SEC filing.